E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
WOMAN BREAST CANCER |
CANCRO DELLA MAMMELLA DELLA DONNA |
|
E.1.1.1 | Medical condition in easily understood language |
WOMAN BREAST CANCER |
CANCRO DELLA MAMMELLA DELLA DONNA |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029104 |
E.1.2 | Term | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Validation of the the fluorescence lymphography with green indocyanine by comparing direct inter and intra-patients with the gold standard method the radio colloid |
Validazione della nuova metodica, la linfografia a fluorescenza, mediante il confronto diretto inter ed intra-pazienti con il metodo gold standard, il radio colloide. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Age ≥ 18
Histologically or cytologically confirmed diagnosis of breast cancer
Early Breast cancer than or equal to 3 cm in diameter;
Clinically negative axilla;
Signature of Informed Consent. |
Età ≥ 18
Diagnosi citologicamente o istologicamente accertata di carcinoma mammario
Tumore Mammario primitivo inferiore o uguale a 3 cm di diametro;
Ascella clinicamente negativa;
Firma del Consenso Informato. |
|
E.4 | Principal exclusion criteria |
Hypersensitivity / allergy known to ICG, sodium iodide or iodine;
hyperthyroidism;
Thyroid cancer;
Patients who are pregnant and / or lactation;
Patients who are taking medicines that affect liver function;
Patients with renal insufficiency;
Patients who are taking drugs that may alter the absorption of green indocyanine
Patients with psychiatric illness or any illness that would impair the ability to provide informed consent for participation in this study. |
Ipersensibilità/allergia nota al ICG, allo ioduro di sodio o allo iodio;
Ipertiroidismo;
Neoplasia tiroidea;
Pazienti in gravidanza e/o allattamento;
Pazienti che stanno assumendo medicinali che influenzano la funzionalità epatica;
Pazienti con insufficienza renale;
Pazienti che stanno assumendo farmaci che possono alterare l’assorbimento del Verde Indocianina;
Pazienti con malattie psichiatriche o con qualsiasi malattia, che compromettano la capacità di fornire il proprio consenso informato per la partecipazione a questo studio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The study aims is to demonstrate the equivalence of the two methods. It is assumed that the radioactive tracer (Gold Standard) captures at least 97% of the lymph nodes, the percentage of discrepancy between the two tests is 6% and sets the margin of equivalence of the difference in performance between the two methods to = 5% . |
Lo studio si prefigge di dimostrare l’equivalenza delle due metodiche. Si assume che il tracciante radioattivo (Gold Standard) capti almeno il 97% dei linfonodi, che la percentuale di discordanza tra i due test sia del 6% e si fissa il margine di equivalenza della differenza delle prestazioni tra le due metodiche a d=5%. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |